|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: OCEL1 |
Gene summary for OCEL1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | OCEL1 | Gene ID | 79629 |
| Gene name | occludin/ELL domain containing 1 | |
| Gene Alias | FWP009 | |
| Cytomap | 19p13.11 | |
| Gene Type | protein-coding | GO ID | NA | UniProtAcc | Q9H607 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 79629 | OCEL1 | HTA11_2487_2000001011 | Human | Colorectum | SER | 6.88e-05 | 2.77e-01 | -0.1808 |
| 79629 | OCEL1 | HTA11_347_2000001011 | Human | Colorectum | AD | 6.05e-06 | 2.55e-01 | -0.1954 |
| 79629 | OCEL1 | HTA11_411_2000001011 | Human | Colorectum | SER | 4.19e-04 | 6.08e-01 | -0.2602 |
| 79629 | OCEL1 | HTA11_3361_2000001011 | Human | Colorectum | AD | 1.29e-03 | 2.96e-01 | -0.1207 |
| 79629 | OCEL1 | HTA11_696_2000001011 | Human | Colorectum | AD | 4.01e-04 | 2.16e-01 | -0.1464 |
| 79629 | OCEL1 | HTA11_1391_2000001011 | Human | Colorectum | AD | 7.53e-05 | 2.69e-01 | -0.059 |
| 79629 | OCEL1 | HTA11_5212_2000001011 | Human | Colorectum | AD | 2.12e-04 | 3.79e-01 | -0.2061 |
| 79629 | OCEL1 | LZE4T | Human | Esophagus | ESCC | 1.37e-03 | 1.72e-01 | 0.0811 |
| 79629 | OCEL1 | LZE7T | Human | Esophagus | ESCC | 3.41e-02 | 1.18e-01 | 0.0667 |
| 79629 | OCEL1 | LZE20T | Human | Esophagus | ESCC | 6.46e-03 | 1.13e-01 | 0.0662 |
| 79629 | OCEL1 | LZE24T | Human | Esophagus | ESCC | 2.45e-12 | 5.10e-01 | 0.0596 |
| 79629 | OCEL1 | LZE21T | Human | Esophagus | ESCC | 5.59e-03 | 1.66e-01 | 0.0655 |
| 79629 | OCEL1 | LZE6T | Human | Esophagus | ESCC | 7.10e-04 | 2.26e-01 | 0.0845 |
| 79629 | OCEL1 | P1T-E | Human | Esophagus | ESCC | 1.78e-11 | 3.91e-01 | 0.0875 |
| 79629 | OCEL1 | P2T-E | Human | Esophagus | ESCC | 2.81e-07 | 6.24e-02 | 0.1177 |
| 79629 | OCEL1 | P4T-E | Human | Esophagus | ESCC | 1.41e-09 | 2.39e-01 | 0.1323 |
| 79629 | OCEL1 | P5T-E | Human | Esophagus | ESCC | 4.44e-20 | 2.99e-01 | 0.1327 |
| 79629 | OCEL1 | P8T-E | Human | Esophagus | ESCC | 1.03e-24 | 5.20e-01 | 0.0889 |
| 79629 | OCEL1 | P9T-E | Human | Esophagus | ESCC | 8.67e-06 | 9.52e-02 | 0.1131 |
| 79629 | OCEL1 | P10T-E | Human | Esophagus | ESCC | 6.28e-12 | 1.65e-01 | 0.116 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| OCEL1 | SNV | Missense_Mutation | rs201983831 | c.29N>T | p.Pro10Leu | p.P10L | Q9H607 | protein_coding | tolerated_low_confidence(0.44) | benign(0) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
| OCEL1 | insertion | In_Frame_Ins | novel | c.654_655insCAC | p.Glu218_Phe219insHis | p.E218_F219insH | Q9H607 | protein_coding | TCGA-A7-A0CE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| OCEL1 | deletion | Frame_Shift_Del | novel | c.358delN | p.Leu120CysfsTer37 | p.L120Cfs*37 | Q9H607 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| OCEL1 | SNV | Missense_Mutation | novel | c.387G>T | p.Lys129Asn | p.K129N | Q9H607 | protein_coding | deleterious(0.03) | benign(0.154) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
| OCEL1 | SNV | Missense_Mutation | c.756C>A | p.Phe252Leu | p.F252L | Q9H607 | protein_coding | deleterious(0) | possibly_damaging(0.892) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR | |
| OCEL1 | SNV | Missense_Mutation | c.451N>T | p.Leu151Phe | p.L151F | Q9H607 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-EI-6882-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| OCEL1 | insertion | Frame_Shift_Ins | novel | c.572_573insCA | p.Arg191SerfsTer8 | p.R191Sfs*8 | Q9H607 | protein_coding | TCGA-AM-5820-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| OCEL1 | insertion | In_Frame_Ins | novel | c.573_574insGGCCTC | p.Arg191_Gln192insGlyLeu | p.R191_Q192insGL | Q9H607 | protein_coding | TCGA-AM-5820-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| OCEL1 | deletion | Frame_Shift_Del | c.284delN | p.Arg97AlafsTer60 | p.R97Afs*60 | Q9H607 | protein_coding | TCGA-CM-5861-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |||
| OCEL1 | SNV | Missense_Mutation | c.528N>A | p.Phe176Leu | p.F176L | Q9H607 | protein_coding | tolerated(0.28) | benign(0.003) | TCGA-AJ-A5DW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |